SHIXIA HUANG to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications SHIXIA HUANG has written about Xenograft Model Antitumor Assays.
Connection Strength
0.105
-
Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways. Br J Cancer. 2020 08; 123(4):568-579.
Score: 0.024
-
Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers. Cancer Res. 2018 05 15; 78(10):2732-2746.
Score: 0.021
-
A new mild hyperthermia device to treat vascular involvement in cancer surgery. Sci Rep. 2017 09 12; 7(1):11299.
Score: 0.020
-
miR-130b directly targets ARHGAP1 to drive activation of a metastatic CDC42-PAK1-AP1 positive feedback loop in Ewing sarcoma. Int J Cancer. 2017 11 15; 141(10):2062-2075.
Score: 0.020
-
Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res. 2008 Sep 15; 68(18):7493-501.
Score: 0.011
-
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008 Feb 01; 68(3):826-33.
Score: 0.010